# Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients.

> **NCT04700709** · PHASE4 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 158 (estimated)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Sirolimus Tab.
- **DRUG:** Mycophenolate Mofetil Cap./Tab.

## Key facts

- **NCT ID:** NCT04700709
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-01
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700709, "Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04700709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*